Please assess the completion status of the following clinical trial:

Trial Title: Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Understand and voluntarily sign an informed consent form.~* Age \>=18 years at the time of signing the informed consent form.~* Able to adhere to the study visit schedule and other protocol requirements.~* Relapsed or refractory AML (\>30% blasts, FAB classification)with karyotype abnormalities involving monosomy 5 or del(5q) or MDS and t-MDS INT-2 or HIGH according to IPSS classification with karyotype abnormalities involving monosomy 5 or del(5q) either previously treated or untreated~* Not eligible for an immediate allogeneic HSCT (due to donor unavailability)~* All previous MDS or AML specific therapy with exception of corticosteroids not exceeding doses of 10mg/day prednisone must have been discontinued at least 1 week prior to study enrollment.~* Non-hematological toxicity (except alopecia) resulting from previous treatment must be resolved to WHO CTC Grade ≤ 2.~* ECOG performance status of \< 3 at study entry.~* Laboratory test results within these ranges:Serum creatinine \<= 2.0 mg/dL, Total bilirubin \<= 3 x ULN, AST (SGOT) and ALT (SGPT) \<= 3 x ULN~* Females of childbearing potential must agree to use a reliable form of contraception or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; and 3) for at least 28 days after discontinuation from the study.~Exclusion Criteria:~* Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.~* Pregnant or breast feeding females. (Lactating females must agree not to breast feed while on study).~* Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.~* Known hypersensitivity to thalidomide, lenalidomide, 5-azacitidine or mannitol.~* Myocardial infarction within 6 months before study entry, New York Heart Association Class III or IV heart failure, uncontrolled angina or severe uncontrolled ventricular arrhythmias.~* The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.~* Uncontrolled lung disease.~* Known positive for HIV or acute infectious hepatitis, type A, B or C.~* Participation in another clinical study in the 4 weeks prior to enrollment or during this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azacitidine and Lenalidomide (Type: EXPERIMENTAL): Azacitidine 75 mg/m² SC days 1-5 every 28 days for a maximum of 8 cycles and Lenalidomide 10 - 25 mg PO days 6-19 every 28 days for a maximum of 8 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).